To construct a clinical pharmacist intervention strategy for tislelizumab injection in the treatment of advanced non-small cell lung cancer (NSCLC) and evaluate its practical effects.

Patients with advanced NSCLC admitted to our hospital were divided into control group and treatment group. The control group received routine pharmaceutical care, while the treatment group received a clinical pharmacist intervention strategy. Therapeutic efficacy, incidence of immune-related adverse events (irAEs), incidence of grade ≥3 irAEs, treatment-related drug withdrawal rate, medication adherence, quality of life and satisfaction with pharmaceutical care were compared between the two groups.

A total of 106 patients were included, including 53 in control group and 53 in treatment group. After treatment, the objective response rates (ORR) of treatment group and control group were 47.17% and 28.30%, respectively; the disease control rates (DCR) were 60.38% and 39.62%, respectively. The above indicators in treatment group were statistically significantly higher than those in control group (all P<0.05). The incidences of irAEs in treatment group and control group were 39.62% and 60.38%, respectively; the incidences of irAEs≥grade 3 were 13.21% and 30.19%, respectively; the treatment-related discontinuation rates were 9.43% and 24.53%, respectively. The above indicators in treatment group were statistically significantly lower than those in control group (all P<0.05). After treatment, the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire–lung cancer 13 (EORTC QLQ-LC13) scores for treatment group and control group were (50.15±9.06) and (53.94±7.19) points, respectively, with treatment group statistically significantly lower than control group (P<0.05). The satisfaction rate of pharmaceutical services in treatment group was 90.57%, statistically significantly higher than control group’s 75.47% (P<0.05).

The clinical pharmacist intervention strategy can improve medication adherence to tislelizumab injection, reduce immune-related adverse events and treatment interruption, improve quality of life, and enhance satisfaction with pharmaceutical care, thereby contributing to better clinical outcomes.